This trial compares pazopanib to placebo as maintenance treatment over 2 years in patients
with retroperitoneal and visceral high-risk soft tissue sarcomas after multimodal treatment
including prior neo- and/or adjuvant doxorubicin / ifosfamide chemotherapy with regional
hyperthermia.